NASDAQ authorized Stem Cell Authority Ltd. (SCAL), the company which possesses the exclusive rights for the collection and storage of human umbilical cord matrix stem cells, to be publicly traded on July 6, 2006.
NASDAQ authorized Stem Cell Authority Ltd. (SCAL), the company which possesses the exclusive rights for the collection and storage of human umbilical cord matrix stem cells, to be publicly traded on July 6, 2006.
The Kansas State University Research Foundation has filed an application for a patent pertaining to the methods for the collection, storage and biotechnology and therapeutic use of umbilical cord matrix stem cells, and has granted Stem Cell Authority Ltd. and its subsidiary company the exclusive license to collect and cryogenically store human umbilical cord matrix stem cells. Thus, the collection and storage of human pluripotent umbilical cord matrix stem cell must be authorized by Stem Cell Authority Ltd. The company also has the right to grant sublicenses.
Recent evidence indicates that the umbilical cord matrix stem cells can differentiate into neurons, glia, skeletal muscle cells, heart muscle cells, bone cells, cartilage cells and liver cells. Published work indicates that the human umbilical cord matrix stem cells are therapeutically useful in an animal model of Parkinson’s disease. Therefore, the umbilical cord matrix stem cells may have the potential for treating neurological diseases. In contrast, umbilical cord blood stem cells are used clinically to treat conditions calling for bone marrow stem cell transplant. These diseases include certain cancers and in-borne errors in metabolism.
Stem Cell Authority Ltd. collects the matrix cells from the Wharton’s jelly which is within the human umbilical cord. The matrix cells are collected safely and painlessly without risk to the child after birth. The collection of the matrix stem cell is compatible with collection of umbilical cord blood stem cells. Thus, Stem Cell Authority Ltd. is the ethical and non-controversial alternative to obtain human stem cells for cryogenic storage of both umbilical cord blood and the matrix stem cells. Stem Cell Authority Ltd. has the exclusive right to offer this service to its customers, placing it in a strong position within the biotech market.
Stem Cell Authority Ltd. is the only entity worldwide that is permitted to collect and store the umbilical cord’s pluripotent or matrix stem cells, which have the potential to be one of the most important sources of stem cells available. The company is poised to become a market leader in this expanding biotech industry.
